focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.825
Bid: 1.80
Ask: 1.85
Change: 0.048 (2.46%)
Spread: 0.05 (2.778%)
Open: 1.95
High: 1.998
Low: 1.998
Prev. Close: 1.95
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Distribution agreement

9 Mar 2021 07:00

RNS Number : 5536R
Genedrive PLC
09 March 2021
 

 

 

genedrive plc

("genedrive" or the "Company")

 

Genedrive enters distribution agreement with Mountain Horse Solutions

Distribution of genedrive's Military Assays and Instrument in the United States

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that it has entered into an agreement for the distribution of the Company's military pathogen detection assays in the United States with Mountain Horse Solutions ("Mountain Horse"), a military contracting specialist to U.S. Federal, State, and Local Government customers.

 

genedrive has a unique product with regard to military CBRNE1 requirements. The Genedrive® BioPlex range of products was developed to the U.S. Department of Defense's (U.S. DoD) product specification with the help of U.S. DoD funding. Designed for field portability and rapid determination of biothreats from pathogens, the Genedrive BioPlex system was developed over a period of five years and has been approved to deployment stage.

 

Contracting with the U.S. Government can be challenging and time consuming. The Company believes that establishing new, local representation in the United States with identified contacts in this highly specialised field will help drive broader product uptake. Organisations like Mountain Horse are already contracted with the U.S. Government, which includes existing framework purchasing agreements, providing an opportunity for more rapid order placement and replenishment of products without the need for new contracts to be negotiated.

 

Bill Allen, President of Mountain Horse Solutions, said: "We are delighted to be working with genedrive with these exciting pathogen detection products. The addition of genedrive's assays to our portfolio of CBRNE mission critical products provides a unique offering of combat-ready sampling and detection devices."

 

David Budd, CEO of genedrive plc, said: "The agreement allows the supply of our BioPlex pathogen detection assays through Mountain Horse, a military contracting specialist who has a number of existing framework contracts with target clients such as the U.S. DoD. We believe that they have both the industry sector knowledge and existing commercial arrangements to increase the exposure of our products and gain new customer opportunities within the various branches and departments of the DoD and U.S. Government."

 

1. Chemical Biological Radiological, Nuclear and Explosive

 

For further details please contact:

 

genedrive plc

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO

 

 

 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Oliver Jackson

 

 

 

finnCap (Joint Broker)

+44 (0)20 7220 0500

Geoff Nash / Kate Bannatyne / Alice Lane

 

 

 

Walbrook PR Ltd (Media & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive® Point of Care version of the assay, both based on Genedrive® chemistry.

 

About Mountain Horse Solutions 

Mountain Horse Solutions supplies rapid response customized equipment, systems, and training for infectious disease, security, technology, chemical, biological, radiological, nuclear, and explosive (CBRNE) hazards. We specially design innovative solutions, to meet the individual unique threats, needs, and requirements of the military, and first responders. Our team of professionals from around the globe has extensive experience with commercial, DOD, and U.S. Federal Government customers. Mountain Horse Solutions serves organizations, agencies, and contractors worldwide. To find out more visit: www.mtnhorse.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRBIGDXBXGDGBI
Date   Source Headline
29th Nov 20167:00 amRNSUpdate on CFO Appointment
17th Nov 20167:00 amRNSCE-IVD Certification for Human Genotyping Test
11th Nov 20165:47 pmRNSNotice of AGM
11th Oct 20167:00 amRNSPreliminary Results for the year end 30 June 2016
21st Sep 20167:00 amRNSNotice of Preliminary Results
21st Sep 20167:00 amRNSAppointment of Chief Financial Officer
10th Aug 20167:00 amRNSGenedrive Assay used in STOP-HCV-1 Clinical Trial
2nd Aug 20167:00 amRNSTrading Update
29th Jul 20165:58 pmRNSTotal Voting Rights
25th Jul 20167:00 amRNSRe change of name, TIDM and website address
14th Jul 20163:56 pmRNSHolding(s) in Company
14th Jul 20168:19 amRNSDirector/PDMR Shareholding
14th Jul 20168:18 amRNSHolding(s) in Company
13th Jul 20162:49 pmRNSHolding(s) in Company
12th Jul 20169:05 amRNSDirector/PDMR Shareholding
11th Jul 201611:34 amRNSResult of General Meeting and Change of Name
23rd Jun 20164:54 pmRNSPosting of Shareholder Circular
23rd Jun 20167:00 amRNSProposed Placing and Amendment to GHIF Bond
7th Jun 20167:00 amRNSBusiness Update
3rd May 20167:00 amRNSSuccessful Clinical Trial of Genedrive®
18th Apr 20167:00 amRNSEpistem Begins Full Commercial Launch of Genedrive
7th Apr 20164:54 pmRNSDirector/PDMR Shareholding
31st Mar 20167:00 amRNSInterim Results
21st Mar 20167:42 amRNSFunding award from US Department of Defense
19th Feb 20167:00 amRNSUpdate on CEO Appointment
18th Feb 20167:00 amRNSAnnounces Successful Assessment of Genedrive
13th Jan 20167:00 amRNSEpistem Appoints David Budd as CEO
16th Dec 20152:18 pmRNSDirector/PDMR Shareholding
16th Dec 20152:11 pmRNSResult of AGM
26th Nov 20154:41 pmRNSHolding(s) in Company
24th Nov 20153:28 pmRNSNotice of AGM
24th Nov 20152:07 pmRNSHolding(s) in Company
28th Oct 20157:00 amRNSPreliminary Results for year ended 30 June 2015
26th Oct 20157:00 amRNSEpistem Holdings Plc - Board Change
20th Oct 20157:00 amRNSNotice of Preliminary Results
15th Oct 20157:30 amRNSDirector/PDMR Shareholding
4th Aug 20157:00 amRNSPre-Close Trading Update and Board Changes
15th Jun 201512:17 pmRNSHolding(s) in Company
8th Jun 20154:49 pmRNSIssuance of Shares
18th May 201512:45 pmRNSNIH Response to UMB proposal
11th May 20153:37 pmRNSAdditional Listing
11th May 201511:53 amRNSDirectorate Change
23rd Apr 20157:00 amRNSRegulatory Approval
13th Apr 20157:00 amRNSUpdate re Indian regulatory approval
2nd Apr 20154:55 pmRNSDirector/PDMR Shareholding
30th Mar 20159:30 amRNSExtension of Director's Options Exercise Period
26th Mar 20157:00 amRNSHalf Yearly Report
11th Feb 20153:21 pmRNSHolding(s) in Company
6th Feb 20157:48 amRNSNotice of Interim Results
12th Jan 201512:19 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.